superbqueentrash-blog1

[superbqueentrash-blog1]

Pemirolast Market -Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Pemirolast is a mast cell stabilizer, which acts as an anti-allergic agent. Pemirolast treats allergic reactions by preventing mast cell degranulation, which stabilizes the mast cell and inhibits the release of inflammatory mediators such as histamines and leukotriene.

Request Sample Copy of this Research Report@ https://www.coherentmarketinsights.com/insight/request-sample/3466

The pemirolast potassium is a light yellow-colored ophthalmic aqueous sterile solution that is used to prevent allergic reactions such as itching in eyes, caused by hay fever, and allergic conjunctivitis. The pemirolast potassium inhibits the release of inflammatory mediators from the eosinophils in the ocular tissue. Pemirolast is also used to treat pulmonary conditions such as bronchial asthma and allergic rhinitis.

Rising incidence of allergic conjunctivitis is expected to propel growth of the global pemirolast market over the forecast period. For instance, according to the article published in the Asia Pacific Association of Allergy, Asthma and Clinical Immunology, in April 2019, simple allergic conjunctivitis affects around 10% to 30% of the population globally.

Moreover, adoption of inorganic growth strategies such as mergers, collaborations, and acquisitions by major players are expected to propel the market growth over the forecast period. For instance, in March 2017, Nipro Corporation, acquired the Tanabe Seiyaku Hanbai Co., Ltd., an alegysal (potassium pemirolast) manufacturing subsidiary of Mitsubishi Tanabe Pharma Corporation. The acquisition is expected to enhance Nipro’s offerings in the global generic drugs market, including alegysal.

Request PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/3466

North America accounted for the largest market share in 2018, owing to high prevalence of allergic rhinitis (hay fever) in the region. For instance, according to the National Health Interview Survey, 2018, around 19.2 million adults and 5.2 million children were diagnosed with allergic rhinitis in the U.S. in 2017. Moreover, increasing prevalence of allergic eye disease in North America is expected to drive the global pemirolast market over the forecast period. For instance, according to the Allergy, Asthma & Clinical Immunology Journal, 2020, around 40% population of North America is affected by allergic eye disease.

Furthermore, increasing cases of pediatric asthma due to air pollution is expected to propel the pemirolast market growth in the Asia Pacific over the forecast period. For instance, according to the global study published by the National Center for Biotechnology Information (NCBI), in April 2019, pediatric asthma cases due to anthropogenic particulate matters in India, China, and Bangladesh were estimated to be around 57%, 51%, and 70%, respectively.

Key players operating in the global market include Santen Pharmaceutical Co., Ltd, Nipro Corporation, Clearsynth, Bristol-Myers Squibb Company, Toronto Research Chemicals Inc., Jiaxing Epochem Pharmtech Co., Ltd., LGM Pharma, Vistakon Pharmaceuticals LLC, and Aescu Pharma, Inc.

Browse the Full Report at

https://www.coherentmarketinsights.com/ongoing-insight/pemirolast-market-3466

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Synthetic Hormones Market Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Synthetic hormones are foreign substances, synthesized in the laboratory and are used for the treatment of hormonal imbalance in the human body. Hormones such as progesterone, estrogen, thyroid hormone, testosterone, and insulin are some of the synthetic hormones used widely for different health conditions. Some examples of the synthetic hormones available in the market are Ferring B.V. product Zomacton injection (Somatropin) which is used to treat growth hormone deficiency in children. Moreover, IBSA Institute Biochimique SA’s product, Tirosint, is also available as a liquid levothyroxine formulation for the treatment of hypothyroidism in individuals suffering from deficiency of thyroid hormone. Some of the manufacturers operating in the global synthetic hormones market are Pfizer Inc., McGuff Pharmaceuticals, Inc. and others.

Request Sample Copy of this Research Report@ https://www.coherentmarketinsights.com/insight/request-sample/3462

Leading manufacturers are indulged in the development of new products in the global synthetic hormone market. For instance, Lyndra Therapeutics Inc. completed pre-clinical trials for an oral contraceptive pill in December 2019. The contraceptive pill is made of a gelatin capsule, which when ingested, produces a star-shaped polymer and releases the synthetic hormones for three weeks in order to prevent pregnancy.

In October 2019, Mayne Pharma signed a 20?year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialize a novel oral contraceptive comprising Estetrol (E4), and Drospirenone, (E4/DRSP) in the United States. The product is expected to be launched in 2021 post U.S. Food and Drug Administration’s (U.S. FDA) approval. Lupin Pharmaceuticals, Inc. received approval from the U.S. FDA in April 2019 for the Testosterone Gel (Strength 1.62%) which is a generic version of AbbVie, Inc.’s (AbbVie) AndroGel 1.62%. It is used for hormone replacement therapy in males who are incapable of producing endogenous testosterone.

According to the Global Reproductive Health, International Federation of Fertility Societies, 2018, prevalence of menopausal hot flashes have been increasing in the United States. Around 23 million women in the age group of 45 to 55 years are expected to experience menopausal symptoms like heavy or irregular bleeding, breast tenderness, and hot flashes, which will increase more physician visits. According to National Center for Biotechnology information (NCBI), 2018, increasing incidence of irregular menstrual cycles has led to an increase in use of oral contraceptives, birth control pills, birth control shots, vaginal rings, hormonal intrauterine devices (IUD) etc. According to American Thyroid Association, 2019, 12% of the U.S population will develop some kind of thyroid condition in their lifetime, and around 20 million Americans have been diagnosed with some kind of thyroid disorders. These factors are expected to boost the global synthetic hormone market growth over the forecast period.

Request PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/3462

According to National Center for Biotechnology Information (NCBI), 2017, some anti-depressants (non-hormonal) such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) (paroxetine (Paxil), citalopram (Celexa) and escitolapram (Lexapro)) were reported to show a decrease in severity of hot flashes in menopausal as well as post-menopausal women compared to synthetic hormones.

The cost effectiveness of the hormonal replacement therapy is one of the important restraining factor. According to NCBI, at least 18 tablets of Vagifem has to be used by the patient per month, therefore, the cost of the medicine per month comes down to $400 – 500 while Paroxetine is to be taken once daily per month, and hence the cost of 30 tablets comes down to $50 – 100. Moreover, Paroxetine is available as an oral dose while Vagifem is a vaginal insert. Hence, patients prefer the oral route of administration over the inserts.

North America is expected to witness significant growth in the global synthetic hormones market over the forecast period owing to widespread presence of several key manufacturers across North America and a large customer base. Moreover, key players are engaged in development and introduction of generic products in the region. For instance, Teva Pharmaceutical Industries Ltd., launched generic version of Vagifem (estradiol vaginal inserts) in the U.S. in July 2019 which is indicated for the treatment of atrophic vaginitis in menopausal women.

Moreover, Clarus Therapeutics, a manufacturer in the U.S., recently received an U.S. FDA approval in March 2019, for the production of a soft gel capsule containing prodrug for the hormone testosterone which will be useful for the hormone replacement therapy in hypogonadal males. Other manufacturers like Pfizer Inc., McGuff Pharmaceuticals, Inc., Lyndra Therapeutics, Inc., American Regent, Inc., Acerus Pharmaceuticals Corporation and Lupin Pharmaceuticals have presence in North America.

The increasing incidence of hormonal imbalance in the population is expected to support growth of the North America synthetic hormones market. Highest incidence of hormonal imbalance have been recorded in the North America region. According to the Global Reproductive Health, International Federation of Fertility Societies, 2018, in the U.S., around 70 million women are over the age of 45 years, out of which, around 58.8% of women are expected to experience hot flashes during the menopausal and post-menopausal stage.  Therefore, increasing incidences of hormonal imbalance across North America are expected to boost the global synthetic hormones market over the forecast period.

Some of the key players operating in the global synthetic hormones market are Pfizer Inc., McGuff Pharmaceuticals, Inc., Lyndra Therapeutics, Inc., Ferring B.V., Slayback Pharma LLC, American Regent, Inc., Endo Pharmaceuticals Inc., IBSA Institute Biochimique SA, Acerus Pharmaceuticals Corporation, and Lupin Pharmaceuticals, Inc.

Browse the Full Report at https://www.coherentmarketinsights.com/ongoing-insight/synthetic-hormones-market-3462

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com                

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Digital Mobile X Ray Devices Market -Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

Digital mobile X-ray is a portable medical devices that is used for the visual representation of bone, ligaments, and other interior body parts. It is used in diagnosis of several diseases and conditions such as fractures, bone dislocation, ligament tear, arthritis, post-surgical complications, and surgical intervention.

The global digital mobile X-ray devices market is estimated to account for US$ 2,767.0 Mn in terms of value in 2019 and is expected to reach US$ 4,787.0 Mn by the end of 2027.

Request a Sample Copy @   https://www.coherentmarketinsights.com/insight/request-sample/3453

High incidence of orthopedic diseases and bone injuries is expected to boost growth of the global digital mobile X-ray devices market over the forecast period. For instance, according to the study ‘Osteoarthritis in Europe: Impact on health status, work productivity and use of pharmacotherapies in five European countries’ that examined the impact of peripheral joint osteoarthritis across five European countries, UK (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high prevalence of peripheral joint osteoarthritis, with majority of cases aging 55-74 years.

Moreover, increasing number of orthopedic procedures is also expected to aid in growth of the market. For instance, according to American Academy of Orthopedic Surgeons, by 2030, primary total joint replacement is projected to increase by 171% and primary total knee replacement is projected to increase by up to 189%, for a projected 635,000 and 1.28 million procedures, respectively, in the U.S.

North America region held dominant position in the global digital mobile X-ray devices market in 2018, accounting for 31.8% share in terms of value, followed by Europe.

High expanses and stringent regulations associated with the clinical trials is expected to hinder growth of the global digital mobile X-ray devices market. In case of diagnostic imaging equipment, clinical trials ideally should be conducted one year prior to the product launch. However, due to the regulatory restrictions, it has become difficult for the manufacturers to conduct early stage trails and establish partnership with local players.

Moreover, inadequate imaging infrastructure in developing countries is also expected to hamper growth of the market. Currently, several developing nations lack adequate imaging infrastructure useful to conduct test and technology implementation compared to the U.S. and other developed nations. This can be attributed to low investment in diagnostic imaging in emerging economies. Moreover, high cost of initial set up and installation of advanced imaging equipment and broadband technology is also limiting their adoption in emerging economies.

Request PDF Brochure:       https://www.coherentmarketinsights.com/insight/request-pdf/3453

Increasing geriatric population is expected to lead to high incidence of orthopedic diseases, thereby offering lucrative growth opportunities for players in the global digital mobile X-ray devices market over the forecast period. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.

Operating digital mobile X-ray devices requires skilled professional. There is low availability of skilled professionals in emerging economies. This issue can be addressed by proper training for operating new imaging devices and computer programs.

Mobile devices segment in the global digital mobile X-ray devices market was valued at US$ 2,370.1 Mn in 2018 and is expected to reach US$ 4,343.7 by 2027 at a CAGR of 7.0% during the forecast period.

Increasing digitalization in the healthcare sector is boosting growth of the global digital mobile X-ray devices market. For instance, in January 2020, Sentara Halifax Regional Hospital (U.S) and its associated medical practices implemented a new digital platform – Sentara eCare— for health care delivery that includes an integrated electronic medical record, patient portal, mobile phone app and registration and billing features.

In emerging economies such as India, several companies offer digital mobile X-ray devices on rent. These companies include KWIPPED Soma Technology, Inc. Chesapeake Medical Systems, and FlexXray.

Major players operating in the global digital mobile X-ray devices market include, Toshiba Corporation, Carestream Health, General Electric Company, Hitachi Ltd., Siemens Healthcare Private Limited, Koninklijke Philips N.V., Shimadzu Corporation, MinXray Inc., Samsung, and KA Imaging.

Major players in the market are focused on adopting various marketing strategies to enhance their market share. For instance, in December 2019, Carestream Health demonstrated new medical imaging technologies that included DRX-Revolution Mobile X-ray System, Focus 35C Detector and Image Suite Software, and a three-dimensional extension of general radiography through digital tomosynthesis (DT) functionality, at the annual meeting of the Radiological Society of North America (RSNA).

Similarly, in December 2019, Samsung showcased ceiling X-ray GC85A and mobile X-ray GM85, which have been granted ATO (Authorization to Operate) for the Risk Management Framework (RMF) program at the annual meeting of the RSNA.

Browse Full Report:

https://www.coherentmarketinsights.com/market-insight/digital-mobile-x-ray-devices-market-3453

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Radiotherapy Market-Global Trends, and Forecast to 2027

Radiotherapy, also known as radiation therapy, uses ionizing radiations that deliver targeted beams of radiation to kill and destroy cancer cells. The advanced technology used in radiotherapy works by bombarding cancerous cells with radiation to kill them, while minimizing damage to the healthy cells around them. Radiotherapy is the most potent and cost-effective treatment for cancer, and when integrated with advanced technologies such as image guided therapy, leads to enhanced control over tumor and toxicity.

Radiotherapy, also known as radiation therapy, uses ionizing radiations that deliver targeted beams of radiation to kill and destroy cancer cells. The advanced technology used in radiotherapy works by bombarding cancerous cells with radiation to kill them, while minimizing damage to the healthy cells around them. Radiotherapy is the most potent and cost-effective treatment for cancer, and when integrated with advanced technologies such as image guided therapy, leads to enhanced control over tumor and toxicity.

Request for a sample copy @

https://www.coherentmarketinsights.com/insight/request-sample/1320

Several types of radiotherapies such as external beam radiation therapy, internal beam radiation therapy/ brachytherapy, and systemic radiation therapy, are available to combat various types of cancers prevalent globally. External beam radiation therapy is used to treat various types of cancers, including brain tumors, bladder cancer, and bone cancers. Brachytherapy is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye, while systemic radiation therapy is often used to treat certain types of thyroid cancers using radioactive iodine.

The global radiotherapy market was valued at US$ 5,253.7 million in 2016 and is expected to witness a robust CAGR of 6.8% over the forecast period (2017 - 2025).

Rising prevalence of oncology diseases such as prostate cancer, lung cancer, and breast cancer, globally is increasing the demand for timely management to reduce mortality associated with such conditions. This in turn, is a major factor augmenting growth of the radiotherapy market. The International Cancer Association, 2014, states that cancer kills more people every year than AIDS, tuberculosis, and malaria combined. This indicated the growing demand for adopting advanced technologies for cancer management. According to the World Cancer Research Fund Organization, 2015, lung cancer is among the most prevalent cancers worldwide contributing 1.9 million or 13% of the total number of new cases diagnosed in 2012. It further states that breast cancer is the second most common cancer prevalent among women, with 1.7 million new cases diagnosed in 2012. Moreover, increasing prevalence of cancer among children is expected to increase the demand for radiation therapy, as it is a highly recommended therapy due to fewer adverse effects associated with it than chemotherapy to accelerate growth of the market as considering the major adverse effects of chemotherapy. According to the International Union against Cancer (UICC) Report, 2017, around 160,000 children are estimated to be diagnosed with cancer and at least 90,000 children are estimated to die of cancer globally.

Get PDF Sample Copy of this Report @

https://www.coherentmarketinsights.com/insight/request-pdf/1320

North America is expected to hold a dominant position in the radiotherapy market, owing to the increasing prevalence of cancer recorded in the U.S. and increasing preference of the novel therapies in comparison to the traditional chemotherapies to minimize side effects associated with chemotherapies. According to the survey conducted by the National Cancer Institute, 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and 595,690 deaths due to cancer were reported. The survey also stated that the public expenditures for cancer care in the U.S. totaled to US$ 125 billion in 2010 and is estimated to reach to US$ 156 billion in 2020, thus raising the demand for radiotherapy for cancer management which will further minimize the economic burden in the region. Furthermore, radiotherapy may cause damage to organs such as the stomach, bowel, liver, and kidneys, which are near the site of treatment, in turn posing as restraining factor for growth of the radiotherapy market.

Radiotherapy is increasingly being adopted for cancer treatment due to its cost-effectiveness. According to the report by The Mesothelioma Center, radiation therapy accounts for an average US$ 2,000 per treatment, whereas the initial treatment cost of chemotherapy is around US$ 7,000. Also, according to a study published in the Journal named Frontiers of Oncology, 2014, the impact of radiotherapy for cancer cure was 40%, compared to 11% of patients by systemic treatments globally. Also, the Royal College of Radiologists states that radiotherapy is a safe, modern, and an efficient targeted cure, contributing to the cure of 40% of cancers, while drug therapy accounts for 10% of cancer cure among patients. Europe is expected to be the fastest-growing region in the radiotherapy market, owing to the increasing number of government initiatives being undertaken for cancer care, in turn increasing the introduction of novel therapies in the global market. For instance, in 2015, the Swedish Government launched the National Cancer Program to make cancer care more equitable and accessible. Moreover, in 2017, the Swedish Testbed for Innovative Radiotherapy was launched as a collaborative platform to enable healthcare providers and market players in Sweden, to test new technology and methods in clinical settings for the development of innovative radiotherapies for cancer treatment. Also, in 2016, National Health Service, England announced US$ 183 million investment to upgrade radiotherapy investment, ensuring patients get access to the latest leading-edge technology, thereby transforming cancer treatment across England.

Major players operating the global radiotherapy market include Accuray Incorporated, Varian Medical Systems, Inc., Elekta AB, Ion Beam Applications S.A., C.R. Bard, Inc., Isoray Medical, Inc., CIVCO Radiotherapy, Hitachi Ltd., Mevion Medical Systems, Inc., and ProTom International, Inc.

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/radiotherapy-market-1320

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com                

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Telemonitoring System Market -Size, Share, Trends, and Forecast to 2026

Telemonitoring system provides patients and professionals with regular measurements of a range of symptoms and physiological parameters. The system can improve access to specialized care in areas with lack of healthcare professionals or in areas where access to healthcare is difficult. It can improve quality of life of patients suffering from chronic diseases and reduce hospital costs. Services such as teleconsultation and teleradiology will help shorten waiting lists, optimize the resources, and enable productivity gains.

Moreover, increased implementation of telehealth will significantly decrease the dependency on hospitals and enable accessibility to proper healthcare services from home. A NTCA-The Rural Broadband Association report published in 2017 stated that telemedicine could save thousand dollars per annum in healthcare costs, thereby, reducing significant cost spent on labor wages, lab cost, medical facility, and transportation.

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/2196

The global telemonitoring system market size was valued at US$ 1.6 billion in 2017 and is expected to witness a CAGR of 10.1% over the forecast period (2018 – 2026).

Source: Coherent Market Insights Analysis (2018)

Increasing global incidence of chronic diseases, rising geriatric population rate, and government initiatives to promote telehealth are major factors driving the telemonitoring systems market growth. For instance, in the U.S., the new CONNECT (Creating Opportunities Now for Necessary and Effective Care Technologies) for Health Act, introduced in June 2017, is expected to promote cost savings and improve quality care in Medicare through telehealth and remote patient monitoring. Moreover, the act permits the use of telemonitoring systems for patients suffering from chronic conditions. The government is also funding the research and development activities to establish telehealth programs. In 2017, Southwest Telehealth Resource Center (SWTRC) received US$ 975,000 cooperative agreement grant from the Federal Office for the Advancement of Telehealth (OAT). The grant will help in adoption of telehealth programs in clinics, hospitals, and public health offices in the underserved areas in the U.S.

Download PDF Report Sample @

https://www.coherentmarketinsights.com/insight/request-pdf/2196

However, there are certain limitations with the usage and adoption of telemonitoring systems such as development of trust of care providers who are not actually present at place, difficulty in understanding the technology, and concerns regarding medical data privacy. Risk management from a distance has been a concern, often dependent on the level of training given to the individual reviewing the data. Clinicians at a distance will find it difficult to communicate if the patient develops impaired senses and dementia.

Moreover, advancements in technology can increase the cost of equipment and implementation. Other potential drawbacks include user interface problems, technical problems, and safety concerns such as data loss and confidentiality. All these factors collectively confine the adoption of telemonitoring systems, thereby restraining the telemonitoring systems market growth.

On the basis of region, the global telemonitoring system market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America telemonitoring system market is expected to witness significant growth over the forecast period, owing to increasing adoption of telemonitoring systems in the U.S. The demand for telemonitoring systems in the country is driven due to strong economy and rising trends of home nursing facilities. According to the Centers for Medicare & Medicaid Services, around 12 million individuals received care from over 33,000 providers in 2010. In 2009, annual expenditures for home health care was around US$ 72.2 billion.

Asia Pacific telemonitoring systems market is expected to grow at lucrative CAGR, owing to increasing number of diabetes and cardiovascular disorder patients. Moreover, a huge population in this region lives in economically backward areas with poor or no healthcare facilities. Therefore, implementation of low cost telemonitoring systems can increase the adoption of telehealth in the region. According to the American Heart Association 2016 report, premature mortality in terms of years of life lost because of cardiovascular disease in India increased by 59%, from 23.2 million in 1990 to 37 million in 2010.

Key players operating in the global telemonitoring system market include Abbott Laboratories, Allscripts Healthcare Solutions Inc., AMD Global Telemedicine, Inc., Cisco Systems, Inc., Care Innovations LLC, General Electric Company, Honeywell Life Care Solutions, InTouch Health, Koninklijke Philips N.V., McKesson Corporation, Medvivo Group Ltd., Medtronic Plc, Nihon Kohden, Siemens Healthineers AG, St Jude Medical, Tunstall Healthcare Group Ltd, and Vidyo, Inc.

Browse More Information @

https://www.coherentmarketinsights.com/market-insight/telemonitoring-system-market-2196

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Orlistat Market – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Orlistat is a drug designed to treat obesity. Primary function of Orlistat is to prevent absorption of fat from the diet consumed by humans. It prevents absorption of fats by acting as lipase inhibitors, which eventually reduce the calorie intake. Orlistat works by inhibiting pancreatic and gastric lipases, pancreatic and gastric enzymes breakdown triglycerides in the intestine. When activity of lipase is blocked, triglycerides from the diet are not hydrolyzed into absorbable-free fatty acids, instead remain unchanged. Orlistat also helps in reducing blood pressure and prevents the onset of type 2 diabetes in obese people. Orlistat medication does not allow one to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.

Request a Sample Copy@

https://www.coherentmarketinsights.com/insight/request-sample/1878

Increasing number of awareness campaigns for weight management is expected to be a major driver for Orlistat market growth. For instance, in 2013, Roche Holding AG, a pharmaceutical company, launched its new campaign ‘New You Weight Consciousness Advocacy Campaign’, with an aim to increase awareness among the populace regarding obesity and its treatment options. Such awareness campaigns is expected increase the adoption of weight management medication treatments, which in turn, is expected to boost growth of the Orlistat market size.

Re-launch of Orlistat products is expected to drive the market growth. For instance, in February 2018, H2 Pharma, LLC. partnered with Cheplapharma Arzneimittel GmbH and re-launched Xenical Capsules, which was acquired from F.Hoffman-La Roche. Xenical capsules were re-launched to increase awareness regarding medication related to weight management, this in turn, is expected to boost orlistat market growth.

Robust pipeline is expected to boost the market growth over the forecast period. For instance, orlistat by University of Texas South Western Medical center is in phase 2 since 2015. Orlistat is used for the treatment of hyperlipoproteinemia type 1. Hyperlipoproteinemia type 1 is caused due to deficiency of lipoprotein lipase. SLx-4090 by University of Texas South Western Medical center is in phase 2 to study its effectiveness in combination with Orlistat. SLx-4090 is used to treat high blood fat level mostly observed in hyperlipoproteinemia type 1 patients.

Rising prevalence of obesity is expected to fuel orlistat market growth. According to a survey conducted by National Family Health Survey in 2015, in India, over 9.8 million men and over 20 million women were recorded to be obese. India stands second-highest in the world for obese children, with the number constantly increasing by 3-5 million patients every year.

Download PDF Report Sample @

https://www.coherentmarketinsights.com/insight/request-pdf/1878

Availability of alternate methods such as devices that reduce fat, in turn, pose as a major factor restraining growth of the Orilstat market. For instance, Ultra shape fat melting device helps remove body fat using pulsed ultrasound waves that neither use heat nor cold to remove body fat.

North America is expected to hold a dominant position in the global orlistat market, owing to high prevalence of obesity in the region. According to a study conducted by National Institute of Health in 2016, over 38% of adults aged 20 years and above are obese, over 17.2% of children aged 7 years and above are obese, and over 30% of the population is considered to be overweight in the U.S. According to a study conducted by World Health Organization, in 2015, over 40 million children aged 5 years and above were overweight in the U.S. Thus, high prevalence of obesity is expected to fuel North America Orlistat market growth over the forecast period.

Europe Orlistat market is expected to show significant growth due to expected launch of new generic version of Orlistat over the forecast period. For instance, in 2011, Teva Pharmaceutical Industries Ltd., launched generic version of Xenical Capsules in the U.K., which was manufactured by Roche Holding AG. Xenical Capsules is used for the treatment of obesity as well as for those whose BMI is greater than or equal to 30kg/m2 and overweight patients. This in turn, is expected to boost Orlistat market growth, as the drug seems more affordable thus, being accessible to a large pool of patients.

Key players operating in the Orlistat market include Roche Holding AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd, Sandoz Pharmaceuticals, STADA–VN J.V. Co., Ltd., Hexal AG., National Company for Pharmaceutical Industry, Lunan Pharmaceutical group Corporation Ltd., ZEIN Pharmaceutical Co. Ltd., HISUN Pharmaceuticals Co. Ltd., Taj Pharmaceuticals Ltd., D.M. Pharma, China Zhongshan Pharma Co. Ltd., and Kabir Life Sciences and Research Pvt. Ltd.

Browse Full Report:

https://www.coherentmarketinsights.com/ongoing-insight/orlistat-market-1878

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Contract Research Organization Services Market Size, Share, Industry Insights, Trends, Outlook, and Analysis, 2020-2027

The contract research organization services are the organizations that provide support to the biopharmaceutical or biotechnological industries and academic institutes in the form of outsourced pharmaceutical research services. The CROs work for both drugs and medical devices and also range from large, international full service organizations to small niche specialty groups to fulfill the clients’ requirement. Initially, the pharmaceutical companies used to carry their own discovery work, along with every other elements to get the drug or medical device in the market. But nowadays, any research work required by biotechnology or pharmaceutical companies from designing assay to planning and running the clinical trials are outsourced from CROs. Outsourcing or partnering with a CROs by the biotechnological companies provide a strategic benefit to the manufacturers, such as cost and time saving in the development and approval process of new drug or therapeutic device, which is expected to increase the demand for CROs.

Furthermore, increasing demand for effective biotherapies and increasing competition between manufacturers to discover new drugs are expected to foster growth of CROs market. Increasing need for product development is leading to high demand for experience and high skilled professionals to implement and conduct the biotechnological research and clinical trials, which can be provided by CROs.

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/1592

Increasing number of Food and Drug administration (FDA) approvals are supporting the growth of biopharma industry, which in turn is fuelling growth of the CROs market. According to article published in Nature, the U.S. FDA approved 46 novel drugs for various indication by the agency’s Center for Drug Evaluation and Research (CDER) in 2017 and 22 drugs in 2016. As the drug companies and few research institutes face challenges in marketing their product due to limited resources and huge capital investment, which decreases the affordability of errors in research work. Therefore CROs play an important role in reducing the cost of research and help in successful clinical development program, which is the most important step of drug development process. As developing a safe and efficacious biological product for human is demonstrated through clinical trials.

Furthermore, stringent regulatory policies for drug development make process more complex, as it required more resources to develop new drugs, devices, and biologics.  These process requires expertise in broad scientific disciplines of preclinical, clinical, ancillary clinical in chemistry, packaging, manufacturing, project management, and regulatory affairs which are provided by the CRO’s, considered as a major reason for drug companies to outsource clinical trials to CROs. Besides, the pharmaceuticals & biopharmaceutical companies are collaborating to undergo clinical trials with CROs to undergo the drug development process.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1592

For instance, in May 2018, Ritter Pharmaceuticals, Inc. a developer of novel therapeutic products signed an agreement with the clinical research organization (CRO) Medpace to conduct the first of two pivotal Phase 3 clinical trials for RP-G28 in patients with lactose intolerance (LI).

North America market accounted for the largest share in the contract research organization services market, followed by Europe in 2016. This is attributed to increasing number of biotechnology-based companies with rising demand for CROs outsourcing services. Furthermore, increasing number of clinical trials and robust pipeline of Novartis, AstraZeneca, Merck and Pfizer, Inc. in the North America region are the factors responsible for growth of market in North America region over the forecast period.

In Asia Pacific region, the countries such as China and India particularly have increasing number of clinical trials for many application areas. Furthermore, due to large patient population, these countries provides a huge opportunity to the manufactures to market their drugs in Asia Pacific region, which is considered as major driver for rapid growth of CRO services. Besides, in some cases, the multinational companies are not allowed to conduct first-in-human Phase I studies in India and China where CROs plays a vital role to conduct such projects under such circumstances.

Furthermore, ongoing adoption of international standards and patent protection laws are been improved over the years particularly in India, China, and Japan. For instance, International Conference on Harmonization (ICH) Guidance document on Good Clinical Practice (GCP) followed by U.S. and Europe is been now adopted in India, Japan, and China. Hence the entrance of CROs in Asia Pacific region helps to provide clinical, regulatory infrastructure and practices in this region.

The Contract research organization players are involved in acquisition to expand the geographical presence of the CROs. For instance, in April 2018, Frontage Laboratories, Inc. an early-stage contract research organization located in China and the U.S. acquired Concord Biosciences, a preclinical organization based in Cleveland, OH aiming the company’s goal to build a global CRO with integrated services. Furthermore, in May 2018, RxCelerate acquired Total Scientific, a CRO focused in bioanalysis, protein assays and gene-phenotype association.

Key players operating in the global contract research organization services market include IQVIA, LabCorp, PAREXEL, ICON plc, PPD, PRA Health Sciences, Syneos Health, Charles River, Wuxi PharmaTech, Medpace Holdings, SGS, Envigo, and MPI Research.

Browse the Full Report at

https://www.coherentmarketinsights.com/ongoing-insight/contract-research-organization-services-market-1592

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Gout Disease Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.

The global gout disease treatment market was valued atUS$ 2,385.7million in 2018, and is expected to exhibit a CAGR of6.7%during the forecast period (2019–2027).

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/3082

Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.

Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.

Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3082

Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.

Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.

Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/gout-disease-treatment-market-3082

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Smoke Evacuation System Market- Size, Share, Outlook, and Opportunity Analysis 2020 – 2027

Smoke evacuation systems are used to release smoke produced during surgery at surgical site. These system uses high-flow vacuum to remove smoke out of the surgery room. Surgical smoke is the gaseous by-product of electrosurgery, laser tissue ablation, ultrasonic scalpel dissection, drilling or burring, or any other procedure performed using a surgical device. It is essential to remove surgical smoke from the surgical site, as it contains carcinogenic, irritant chemicals, or bio-aerosols which can harm patients or operating room personnel upon inhalation.

Manufacturers such as Buffalo Filter LLC., are engaged in research and development activities, and product launches. For instance, in April 2016, Buffalo Filter LLC launched PlumePen Pro, a surgical smoke evacuation pencil, at the Association of Perioperative Registered Nurses (AORN) surgical conference held in Anaheim, U.S. Moreover, in March 2014, Buffalo Filter LLC., launched VisiClear, a surgical smoke plume evacuator. VisiClear offers SafePort and Whisper technology, which allows quiet, safe, and intuitive surgical smoke removal.

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/3035

Increasing number of laparoscopic surgeries is driving demand for laparoscopic smoke evacuation systems. For instance, according to the Global Surgery Statistics 2018, around 15 million laparoscopic surgeries are performed every year across the globe. Moreover, due to increasing demand of laparoscopic surgery, manufacturers are focusing on developing laparoscopic smoke evacuation products, which is expected to drive the market growth. For instance, CONMED Corporation, offers a large portfolio of laparoscopic smoke management systems. Moreover, Medtronic also offers Valleylab, a laparoscopic smoke evacuators.

The demand of smoke evacuation system is increasing, owing to stringent regulatory requirement of smoke evacuation systems at the surgical site. Such regulations are driving demand for smoke evacuation systems, which is expected to boost growth of the global smoke evacuation system market over the forecast period.

Safety is an important parameter which is maintained at work place and healthcare divisions. It is essential to follow the rules and guidelines for safety and welfare of patients and working personnel. According to the National Institute for Occupational Safety and Health (NIOSH) recommendations, several control measures are required to remove smoke generated during laser/electric surgical procedures, such as local exhaust ventilation (LEV), smoke evacuators, and room suction systems. Moreover, the Center for Disease Control and Prevention (CDC) has also set guidelines related to surgical smoke evacuation systems such as:

Smoke evacuators needed to be placed two inches from the surgical site

Tubing and other disposable items to be replaced after each surgical procedure

Such factors are expected to highlight the importance of using smoke evacuation systems at the surgical site.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3035

Increasing awareness about laser surgery has resulted in significant growth in the number of laser surgeries in U.S. For instance, in 2018, according to American Academy of Ophthalmology, around 700,000 LASIK surgeries are done each year in U.S. According to the American Society of Plastic Surgeons, in 2017, around 17.5 million surgical and minimally invasive cosmetic procedures were performed in the U.S., with an increase by 2% from 2016. These factors are expected to drive the global smoke evacuation system market growth.

The global smoke evacuation system market was valued at US$ 165.0 Mn in 2018 and is expected to witness a CAGR of 5.9% over the forecast period (2020–2027).

The global smoke evacuation system market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in global smoke evacuation system market, owing to presence of key players such as Buffalo Filter LLC., CooperSurgical, Inc., Symmetry Surgical, and others. These manufactures have a broad product portfolio of smoke evacuation systems. For instance, Buffalo Filter LLC offers smoke evacuators, surgical smoke removing pencils and adapters, filters, and others. Moreover, CooperSurgical offers SEECLEAR, a smoke evacuation system, and Symmetry Surgical offers Bovie, a smoke evacuation system. Such extensive product offerings are expected to provide several alternatives to users’ requirements.

Furthermore, Asia Pacific market is estimated to witness significant growth over the forecast period, owing to increasing incidence of cardiovascular diseases such as bypass heart surgeries, improving healthcare systems, and increasing government initiatives for modernization of healthcare infrastructure and facilities. For instance, in 2018 according to NCBI approximately 66% of overall population suffered from CVD diseases.  The rise in prevalence of cardio vascular disorders requiring surgical intervention is expected to drive global smoke evacuation system market growth.

Factors restraining the smoke evacuation system market are product recall of smoke evacuation system and accessories from market. For instance, in March 2015, Microtek Medical Inc., recalled its product smoke evacuation tubing set, because a cohesive band used for packaging of devices contains latex and the product was not labeled as required by 21 CFR, it does not contain a caution note: “The Packaging of This Product Contains Natural Rubber Latex Which May Cause Allergic Reactions”.

Key Players

Key players operating in the Global Smoke Evacuation System Market include Medtronic Plc.,  BOWA-electronic GmbH & Co. KG, CooperSurgical, Inc., Symmetry Surgical, I.C. Medical, Inc., CONMED Corporation, CLS Surgimedics, Stryker Corporation, Surgiform Technologies LLC, Zimmer Biomet, Steris Corporation, and  Applied Medical Technology, Inc.

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/smoke-evacuation-system-market-3035

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com                

Visit our Blog: https://hospitalhealthcareblog.wordpress.com

[superbqueentrash-blog1]

Gout Disease Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.

The global gout disease treatment market was valued atUS$ 2,385.7million in 2018, and is expected to exhibit a CAGR of6.7%during the forecast period (2019–2027).

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/3082

Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.

Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.

Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3082

Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.

Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.

Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/gout-disease-treatment-market-3082

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Smoke Evacuation System Market- Size, Share, Outlook, and Opportunity Analysis 2020 – 2027

Smoke evacuation systems are used to release smoke produced during surgery at surgical site. These system uses high-flow vacuum to remove smoke out of the surgery room. Surgical smoke is the gaseous by-product of electrosurgery, laser tissue ablation, ultrasonic scalpel dissection, drilling or burring, or any other procedure performed using a surgical device. It is essential to remove surgical smoke from the surgical site, as it contains carcinogenic, irritant chemicals, or bio-aerosols which can harm patients or operating room personnel upon inhalation.

Manufacturers such as Buffalo Filter LLC., are engaged in research and development activities, and product launches. For instance, in April 2016, Buffalo Filter LLC launched PlumePen Pro, a surgical smoke evacuation pencil, at the Association of Perioperative Registered Nurses (AORN) surgical conference held in Anaheim, U.S. Moreover, in March 2014, Buffalo Filter LLC., launched VisiClear, a surgical smoke plume evacuator. VisiClear offers SafePort and Whisper technology, which allows quiet, safe, and intuitive surgical smoke removal.

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/3035

Increasing number of laparoscopic surgeries is driving demand for laparoscopic smoke evacuation systems. For instance, according to the Global Surgery Statistics 2018, around 15 million laparoscopic surgeries are performed every year across the globe. Moreover, due to increasing demand of laparoscopic surgery, manufacturers are focusing on developing laparoscopic smoke evacuation products, which is expected to drive the market growth. For instance, CONMED Corporation, offers a large portfolio of laparoscopic smoke management systems. Moreover, Medtronic also offers Valleylab, a laparoscopic smoke evacuators.

The demand of smoke evacuation system is increasing, owing to stringent regulatory requirement of smoke evacuation systems at the surgical site. Such regulations are driving demand for smoke evacuation systems, which is expected to boost growth of the global smoke evacuation system market over the forecast period.

Safety is an important parameter which is maintained at work place and healthcare divisions. It is essential to follow the rules and guidelines for safety and welfare of patients and working personnel. According to the National Institute for Occupational Safety and Health (NIOSH) recommendations, several control measures are required to remove smoke generated during laser/electric surgical procedures, such as local exhaust ventilation (LEV), smoke evacuators, and room suction systems. Moreover, the Center for Disease Control and Prevention (CDC) has also set guidelines related to surgical smoke evacuation systems such as:

Smoke evacuators needed to be placed two inches from the surgical site

Tubing and other disposable items to be replaced after each surgical procedure

Such factors are expected to highlight the importance of using smoke evacuation systems at the surgical site.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3035

Increasing awareness about laser surgery has resulted in significant growth in the number of laser surgeries in U.S. For instance, in 2018, according to American Academy of Ophthalmology, around 700,000 LASIK surgeries are done each year in U.S. According to the American Society of Plastic Surgeons, in 2017, around 17.5 million surgical and minimally invasive cosmetic procedures were performed in the U.S., with an increase by 2% from 2016. These factors are expected to drive the global smoke evacuation system market growth.

The global smoke evacuation system market was valued at US$ 165.0 Mn in 2018 and is expected to witness a CAGR of 5.9% over the forecast period (2020–2027).

The global smoke evacuation system market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in global smoke evacuation system market, owing to presence of key players such as Buffalo Filter LLC., CooperSurgical, Inc., Symmetry Surgical, and others. These manufactures have a broad product portfolio of smoke evacuation systems. For instance, Buffalo Filter LLC offers smoke evacuators, surgical smoke removing pencils and adapters, filters, and others. Moreover, CooperSurgical offers SEECLEAR, a smoke evacuation system, and Symmetry Surgical offers Bovie, a smoke evacuation system. Such extensive product offerings are expected to provide several alternatives to users’ requirements.

Furthermore, Asia Pacific market is estimated to witness significant growth over the forecast period, owing to increasing incidence of cardiovascular diseases such as bypass heart surgeries, improving healthcare systems, and increasing government initiatives for modernization of healthcare infrastructure and facilities. For instance, in 2018 according to NCBI approximately 66% of overall population suffered from CVD diseases.  The rise in prevalence of cardio vascular disorders requiring surgical intervention is expected to drive global smoke evacuation system market growth.

Factors restraining the smoke evacuation system market are product recall of smoke evacuation system and accessories from market. For instance, in March 2015, Microtek Medical Inc., recalled its product smoke evacuation tubing set, because a cohesive band used for packaging of devices contains latex and the product was not labeled as required by 21 CFR, it does not contain a caution note: “The Packaging of This Product Contains Natural Rubber Latex Which May Cause Allergic Reactions”.

Key Players

Key players operating in the Global Smoke Evacuation System Market include Medtronic Plc.,  BOWA-electronic GmbH & Co. KG, CooperSurgical, Inc., Symmetry Surgical, I.C. Medical, Inc., CONMED Corporation, CLS Surgimedics, Stryker Corporation, Surgiform Technologies LLC, Zimmer Biomet, Steris Corporation, and  Applied Medical Technology, Inc.

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/smoke-evacuation-system-market-3035

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com                

Visit our Blog: https://hospitalhealthcareblog.wordpress.com

[superbqueentrash-blog1]

Tympanostomy Products Market- Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

Otitis media is a group of inflammatory diseases of the middle ear. Two types of otitis media are acute otitis media (AOM) and otitis media with effusion (OME). To cure such ear infections, tympanostomy tube are used. This small tube is inserted into the eardrum to keep the middle ear aerated for prolonged period of time, and to prevent accumulation of fluid in the middle ear. These tubes are also used for reducing the risk of ear infections by placing it in the ear to drain out fluid from the middle ear. In some cases, even after the infection is cured, the fluid remains in the ear and this increases the chance of reoccurrence of infection. Therefore, in such cases tubes help in preventing the infection from reoccurring by draining all the fluid from ear.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/3021

Increasing prevalence and incidence of otitis media is expected to drive the global tympanostomy products market growth over the forecast period. For instance, according to a research published in South African Medical Journal in 2014, global incidence rate of acute otitis media is 10.9% and it was estimated that 80% of children will have at least one episode of acute otitis media (AOM) before the age of 3. Furthermore, according to a study published in Formulary Journal in 2014, AOM accounted for healthcare expenditure of around US$ 314 per child per year in the U.S. Moreover, due to increase in incidence of otitis media the manufacturers has started focusing on developing and launching products in market. For instance, in 2017, Preceptis Medical launched Hummingbird TTS ear tube delivery system, an alternative for general anesthesia, which will help placing the ear tube in very less time without using general anesthesia for ear surgeries. Medasil surgical limited offers a variety of tympanostomy products tube of different types such as Shah, Shepard, Mini Shah, and T- tube for treating otitis media. Adept Medical has NeoZoline ventilation tubes for treating otitis media.

Increasing developments and product approvals is expected to drive the global tympanostomy products market growth over the forecast period. For instance, in 2017, AventaMed Ltd. received European regulatory approval for its solo tympanostomy tube device (Solo TTD), used for quick and simple insertion of ear grommets. For this product in July 2019 AventaMed Ltd. has collaborated with Medtech for U.S. Food and Drug Administration (FDA) approval to enter in U.S market.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3021

Among region, North America is expected to hold the dominant position in the global tympanostomy products market over the forecast period due to presence of major manufacturers such as Preceptis Medical, and Henry Schein, Inc. Moreover, according to the National Center for Biotechnology Information (NCBI), in 2014, the prevalence of acute otitis media in Australian children was 7.1% -12.8% and 10.5% -30.3% for active chronic otitis media. Moreover, according to BioMed Central (BMC) 2016 Pediatrics springer publication, in European Countries the disease burden of acute otitis media is found to be increasing in children with 41.4 % 6 months to 2 year.

There are several drawbacks of using tympanostomy tubes which are expected to restrain the global tympanostomy products market growth, such as sometimes the tube may fall out from the ear leaving a small hole in eardrum which needs to be repaired with surgery. Prolonged presence of tube in the ear could lead to scaring in the eardrum which might result in loss of hearing. Another restraining factor affecting growth of the global tympanostomy products market is the availability of alternative treatments such as medication, laser procedures, techniques etc. In medication there are several classes such as oral antibiotic, topical agents, Antihistamines, decongestants, steroids, and others. Laser procedures are also used for treatment of chronic middle ear infections. There are few Osteopathic Manipulative treatment (OMT) techniques available for treating otitis media in children such as galbreath technique and auricular drainage.

Key players operating in the global tympanostomy products market include Medtronic Plc, Olympus Corporation, Medasil Surgical Limited, Preceptis Medical, Acclarent Inc., Henry Schein, Inc, Summit Medical, Adept Medical, Teleflex Medical Ltd, Adventa Med, and BVM Meditech Private Limited

Browse the Full Report at

https://www.coherentmarketinsights.com/ongoing-insight/tympanostomy-products-market-3021

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Vaporizer Market– Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Anesthetic vaporizer is a part of anesthetic machine, which is used to deliver required concentration of anesthetic agent. It is used to deliver volatile anesthetic agents. converts liquid anesthetic agent into vapors and then these vapors are mixed with the fresh gas flow. Vaporizers are available on the basis of variable bypass and measured flow. They are used during surgery procedures to anesthetize patients, in hospitals and surgical centers. They are also used in intensive care units (ICU).

Introduction of technologically advanced vaporizers is expected to boost the global vaporizer market growth. For instance, Drägerwerk AG & Co. KGaA Draeger offers – D Vapor 3000 — a fully automated vaporizer. The vaporizer calculates required amount of dose of anesthetic agent and self-regulates the delivery of the vaporized anesthetic agents. Similarly, GE Healthcare offers – Aladdin Cassette — an electronically controlled vaporizer. It can calculate the dosage of anesthetics agent and also store the data. Each cassette is specific to the anesthetic agent and due to magnetic codification the cassette can identify the anesthetic agent present in it. Such technological advancements are expected to propel the global vaporizer market growth.

Request Sample Copy of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2614

Moreover, initiatives taken by government and other organizations in surgical and anesthetic area, are expected to have a positive impact on the global vaporizer market growth. For instance, in May 2018, 71st session of World Health Assembly was held in Geneva. The assembly included an event regarding surgery and anesthesia management. The objective of the event was to build an effective program for surgery and anesthesia care for women. Therefore, this factor is expected to support the global vaporizer market growth.

North America is expected to hold dominant position in the global vaporizer market. Factor such as presence of qualified anesthesiologists who can operate modernized vaporizers may contribute to increasing adoption of these devices in the medical care. For instance, American Society of Anesthesiologists has proposed a program – Current Reviews in Clinical Anesthesia for anesthesiologists in practice, which commenced from May 1, 2019. The aim of this program is to update the knowledge of anesthesiologists about emerging technological advancements in anesthesia delivery. Therefore, such qualified anesthesiologists may be able to practice modernized vaporizers, thereby boosting the global vaporizer market growth.

Absence of advanced anesthetic vaporizers in emerging regions such as Africa is expected to hinder the global vaporizer market growth. For instance, in 2017, Western Michigan University conducted a comparative study of public and private healthcare system of South Africa. The study revealed that public hospitals had very poor facilities as compared to private hospitals. Even private hospitals had fewer facilities. It indicates that modernized vaporizers may not have been introduced in emerging economies due to lack of supporting healthcare infrastructure. Therefore, these factors are expected to restrain the global vaporizers market growth.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2614

Moreover, anesthetic vaporizers require constant supply of electricity (Aladin Cassette – GE Healthcare product), which may hinder adoption of these devices in emerging economies where there is lack of constant supply of electricity. Some of the hospitals and surgical centers present in emerging economies have poor infrastructure and are unable to provide continuous supply of power. According to the World Data Bank, in 2016, only 26.7% population of Uganda had access to electricity. Therefore, this factor may restrict the global vaporizer market growth in emerging countries in regions such as Africa, Latin America, and Asia Pacific.

Some of the major players operating in the global vaporizer market include, GE Healthcare, Penlon Ltd., Draegerwerk AG & Co. KGaA, Rothacher Medical GmbH, Allied Medical Ltd., Intersurgical Ltd., Kindwell Medical, Vaporizer Sales and Service, Smiths Group plc, and OES Medical.

The global vaporizer market is segmented on the basis of product type, agent type, end user, and region.

Variable Bypass Vaporizer

Plenum

Plenum Vaporizer with Electronic Control

Measured Flow Vaporizer

Desflurane Vaporizer

Direct Injection of Volatile Anesthetics Vaporizer

Get More Information On This Report:

https://www.coherentmarketinsights.com/ongoing-insight/vaporizer-market-2614

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Cell and Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2026

Cell and gene therapy plays a major role in modern healthcare, as they provide concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling.

The global cell and gene therapy market size was valued at US$ 6,020.0 million in 2017 and is expected to exhibit a CAGR of 21.9% over the forecast period (2018 – 2026).

Request for a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2475

Gene therapy aims at influencing the course of various genetic and acquired disorders at the genetic level whereas cell therapy targets various diseases at the cellular level i.e. by restoration of a certain cell population or using cells as carriers of therapeutic carrier. High prevalence of cardiovascular disease is expected to propel demand for cell and gene therapy, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to WHO, in 2012, cancer was the second leading cause of morbidity and mortality globally, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.

Furthermore, introduction of effective guidelines is expected to propel growth of the global cell and gene therapy market over the forecast period. For instance, the U.S. Food and Drug Administration (FDA) included around 28 guidelines documents from 1998 to 2018 regarding various cell and gene therapies.

However, several development challenges such as safety and efficacy issues, lengthy procedures for conducting clinical studies, stringent regulatory framework, and high costs are expected to limit the adoption of cell and gene therapy, thereby hindering the market growth.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2475

North America holds dominant position in the global cell and gene therapy market, owing to high prevalence of genetic disorders. According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in U.S.

Moreover, increasing research and development activities is expected to increase demand for cell and gene therapy. According to the Catalyst report, in December 2018, around 289 novel cell and gene therapies were in development for a variety of diseases, of which around 111 medicines were for cancer and around 28 medicines were for cardiovascular disease. These medicines in development are either in clinical trials or awaiting for approval from the U.S. Food and Drug Administration (FDA).

Major players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.

Browse Report Summery @           https://www.coherentmarketinsights.com/market-insight/cell-and-gene-therapy-market-2475

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Compression Garments and Stockings Market - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Increasing prevalence of varicose veins is expected to boost growth of the global compression garments and stockings market over the forecast period. For instance, according to the American Vein and Lymphatic Society, 2019, over 40 million people in the U.S. suffer from varicose veins.

Moreover, increasing number of orthopedic surgeries is also expected to aid in growth of the market. For instance, according to American Academy of Orthopedic Surgeons, by 2030, primary total joint replacement is projected to increase by 171% and primary total knee replacement is projected to increase by up to 189%, for a projected 635,000 and 1.28 million procedures, respectively, in the U.S.

Europe region held dominant position in the global compression garments and stockings market in 2018, accounting for 46.9% share in terms of value, followed by North America.

Players in the market are required to follow stringent guidelines while production of medical compression garments. Three main objectives must be reached that is optimal therapeutic efficacy, product reliability, and best comfort. A patient with a weak skin, venous ulcer or some other wounds can suffer from shearing due to the garment. This in turn limits the design space for potential conceptual ideas as patient safety is a major concern.

Complications related to improper use of compression stockings, may also limit growth of the market. Although the application of compression stockings appear simple, inappropriately worn stockings can cause significant problems. Such as breaking of skin, especially in older, malnourished patients, and those with thin and brittle skin. 

Ensuring the consistency and repeatability of the applied pressure throughout its use is a major challenge for compression garments. This is owing to the limited sizing options of most compression garments. Key players in the market can focus on integrating sensors in compression garments to enhance their efficacy.

Market players can also focus on developing non-pneumatic anti-shock compression garments as an effective intervention for intradialytic hypotension.

Compression garments segment in the global compression garments and stockings market was valued at US$ 2,178.3 Mn in 2018 and is expected to reach US$ 3,456.7 Mn by 2027 at a CAGR of 5.1% during the forecast period.

The use of specialized compression stockings, sleeves and gloves has increased in patients suffering from lymphedema, an incurable disease. Use of compression stockings can help prevent complications such as tissue damage, swelling, and infection.

High cost of compression stockings has led to increasing demand for including these products under insurance.  Prices for garments vary considerably. According to the Lymphedema Advocacy Group, a patient volunteer organization seeking a federal mandate for insurance coverage, standard-fit arm sleeve costs US$ 81, whereas a custom-made equivalent costs US$ 202. The total cost of these garments can reach US$ 960 for patients that require custom garments. Moreover, compression garments are needed to be replaced two to four times a year, which further increases the healthcare expenditure.

Major players operating in the global compression garments and stockings market include, 3M, BSN Medical, Covidien Ltd. (a Medtronic Plc. company), Medi GmBH & Co KG, SIGVARIS, Therafirm, 2XU Pty. Ltd., Santemol Group Medikal, Leonisa, Inc., Nouvelle, Inc., and Medical Z.

Major players in the market are focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in November 2018, DJO Global, a provider of compression garments, therapeutic shoes and inserts, partnered with SirenMD, becoming the exclusive sales representative for SirenMD’s sports team market.

In October 2018, Parasol Medical, a provider of compression garments used for pain management and physical therapy, signed an agreement with Professional Products, Inc., under which Professional Products, Inc. will have the global rights for the use of Parasol’s MicrobeCare antimicrobial technology in orthopedic and veterinary bracing markets.

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Smart Insulin Pen Market - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Increasing prevalence of diabetes is a major factor boosting growth of the global smart insulin pen market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, concerns about needle-stick injuries is also expected to aid in growth of the market. Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by the needle tips and can occur while using, handling, disassembling, or disposing needles and syringes.

Get Sample Copy of this Report at https://www.coherentmarketinsights.com/insight/request-sample/3436  

Europe region held dominant position in the global smart insulin pen market in 2019, accounting for 58.2% share in terms of value, followed by Asia Pacific.

Limited adoption of smart insulin delivery systems, especially in emerging economies, is expected to hamper growth of the global smart insulin pen market. This is attributed to the high cost of the smart insulin pen, limited reimbursement, and less awareness among the diabetic patients regarding the technology.

Moreover, availability of substitute products such as painless smart insulin patches is also expected to hinder growth of the market. Wearable insulin patches allow more discrete insulin dosing throughout the day providing injection-free delivery of insulin whenever needed thus keeping the blood sugar levels in check.  The patch works faster compared to an insulin pen, is easy to use, and made up of biocompatible material.

Players in the global smart insulin pen market can focus on adopting online distribution channels, owing to increasing number of internet users and high adoption of online shopping. For instance, according to China Internet Network Information Center (CNNIC) (2018), 802 million people in China are now actively using the internet, which accounts for 57.7% of the population.

Get Free PDF Brochure of Research Report:

https://www.coherentmarketinsights.com/insight/request-pdf/3436

Moreover, high prevalence of diabetes in emerging regions is also expected to aid in growth of the market. For instance, according to International Diabetes Federation, the prevalence of type 2 diabetes in Asia Pacific is expected increase over 150% between 2000 and 2035.

Type 2 Diabetes segment in the global smart insulin pen market was valued at US$ 1.2 Mn in 2019 and is expected to reach US$ 4.4 Mn by 2027 at a CAGR of 18.9% during the forecast period.

Start-ups in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Bigfoot Biomedical, a diabetes startup focused on automated insulin delivery via connected insulin pens, initiated its Series C round with an initial tranche of US$ 45 million.

Players in the market are also focused on bringing connected insulin data into the clinical workflow. For instance, in June 2019, Companion Medical partnered with Rimidi, a cloud-based connected care software solution provider, to enable clinicians to analyze real-time insulin dosage integrated with data from connected glucometers and CGMs to remotely refine dosing decisions, all while working within the existing clinical workflow.

Major players operating in the global smart insulin pen market include, DigitalMedics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, and Companion Medical Inc.

Players in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Companion Medical, Inc. entered into a loan and security agreement for up to US$ 27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

Browse the Full Report: at :https://www.coherentmarketinsights.com/market-insight/smart-insulin-pen-market-3436

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[superbqueentrash-blog1]

Latin America Capnography Equipment Market,- Size, Share, Outlook, and Opportunity Analysis, 2019

Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases. It offers a graphic picture of the patient's ventilatory status and detects the presence of pulmonary pathology. It is used in emergency medical services and anesthesia. Capnography is dynamic monitoring of patients with acute respiratory distress conditions such as asthma, chronic obstructive pulmonary disease (COPD), bronchiolitis, and heart failure (32).

Latin America capnography equipment market is estimated to account for US$ 21.7 Mn in terms of value in 2019 and is expected to reach US$ 80.1Mn by the end of 2027.

Ask for the Sample of the Study:

https://www.coherentmarketinsights.com/insight/request-sample/3269

Increasing prevalence of asthma is expected to boost growth of Latin America capnography equipment market over the forecast period. For instance, according to The Global Asthma Report 2018, the prevalence of asthma symptoms was 23% and the prevalence of a medical diagnosis of asthma 12% in Brazil.

Moreover, increasing incidence of COPD is also expected to propel growth of the market. For instance, according to the study ‘Chronic Obstructive Pulmonary Disease in Latin America’, published in January 2019 in the journal Annals of Global Health, the prevalence of COPD in Latin American cities ranged between 6.2 and 19.6% in individuals aged 40 years and above.

Side stream capnographs held dominant position in Latin America capnography equipment market in 2018, accounting for 53.5% share in terms of value, followed by mainstream capnographs.

Although capnography is more effective compared to pulse oximetry in monitoring various respiratory diseases, sedation procedures, and apnea, it is associated with high cost, which is expected to hinder growth of Latin America capnography equipment market. A handheld capnograph costs between US$ 2,200 and US$ 4,000, whereas a handheld pulse oximeter costs around US$ 315.

Moreover, use of capnograph may lead to increased dead space and the patients need to be intubated, which is also expected to hamper growth of the market.  

Increasing number of plastic surgeries is expected to offer lucrative growth opportunities for players in Latin America capnography equipment market. For instance, according to The International Society of Aesthetic Plastic Surgeons (ISAPS) 2018, Brazil has the second highest number of cosmetic procedures in the world.

Moreover, increasing medical tourism in countries across Latin America is also expected to boost growth of the market. For instance, according to the study, ‘Medical Tourists: Incoming and Outgoing, published in January 2019 in the American Journal of Medicine, Mexico is among the top 10 destinations for medical tourism.

Request PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/3269

Side stream capnographs sub-segment product type segment in Latin America capnography equipment market was valued at US$ 4.7 Mn in 2018 and is expected to reach US$ 19.5 Mn by 2027 at a CAGR of 17.0% during the forecast period.

Key players in the market are focused on launching portable real-time capnography devices to expand their product portfolio. For instance, Masimo’s Radius capnography system offers cable-free capnography and automated documentation.

The use of capnography devices in regional oximetry for neonatal and infant patients has also increased in the recent past. In regional oximetry, near-infrared spectroscopy (NIRS) is used to monitor the regional hemoglobin oxygen saturation of blood (rSO2).

Major players operating in Latin America capnography equipment market include, Drägerwerk AG & Co. KGaA, Masimo Corporation, Medtronic, Inc., Nihon Kohden Corporation, Nonin Medical, Inc., Philips Healthcare, Smiths Medical, and Welch Allyn, Inc.

Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in October 2019, Masimo Corporation received CE marking for its Radius Capnography, a portable real-time capnograph with wireless Bluetooth connectivity.

Key players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in February 2019, Medtronic plc announced preliminary results from PRODIGY, a Microstream (TM) Capnography, multi-center study to identify people at high risk for opioid-induced respiratory depression (OIRD), a form of respiratory compromise.

Browse the Full Report at

https://www.coherentmarketinsights.com/market-insight/latin-america-capnography-equipment-market-3269

About us:  

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com              

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/